Barca E.,Psychiatry and Anesthesiology |
Aguennouz M.,Psychiatry and Anesthesiology |
Mazzeo A.,Psychiatry and Anesthesiology |
Messina S.,Psychiatry and Anesthesiology |
And 6 more authors.
Neurological Sciences | Year: 2013
To investigate ANT1 and NF-κB expression in inclusion body myositis (IBM) muscle and to verify their possible roles in the pathogenesis of the disease, we collected muscle samples from five patients with IBM, polimyositis (PM) and controls. p65 form of NF-κB was analyzed using immunocytochemistry, Western blot and EMSA. Western blot of ANT1 was performed and confirmed by gene expression study. Mann-Whitney test was used for groups comparisons. NF-κB (p65) was found over-expressed both with western blot and EMSA, either in IBM or PM patients versus controls (p < 0.01). Expression of ANT1 were lower in IBM samples versus both PM and controls (p < 0.01). ANT1 reduction and NF-κB over-expression in IBM muscle could explain the lack of apoptosis in such disease. Normal ANT1 expression in PM could be related to the scarcity of mitochondrial abnormalities in the disease, but it could also suggest that these two conditions diverge in activating different anti-apoptotic pathways. © 2012 Springer-Verlag. Source
Idolazzi L.,Azienda Ospedaliera Universitaria Integrata |
Adami S.,Azienda Ospedaliera Universitaria Integrata |
Capozza R.,Ospedale CTO A. Alesini |
Bianchi G.,Ospedale La Colletta |
And 10 more authors.
Clinical and Experimental Rheumatology | Year: 2015
Objective: Methotrexate (MTX) is the first choice in the treatment of rheumatoid arthritis (RA), but the doses and regimens vary significantly. For this purpose, we conducted an observational study on the use of MTX for RA in Italy (MARI study). Methods: The MARI study included 1,327 RA patients on MTX treatment for at least 12 months, at 60 Italian rheumatology units. Concomitant medications with corticosteroids, other DMARDs or biological therapies were recorded. The clinical assessment included the Disease Activity Score 28 (DAS28) and the serological positivity for the rheumatoid factor or for the anti-citrullinated protein antibodies. Results: The included patients were treated with either oral (n=288) or parenteral (n=1039) MTX. Only 15.5% of the total number of the patients was on adequate MTX dose (i.e. ≥15 mg for the oral route of administration and >12 mg for the parenteral one). The initially established MTX dose was modified in 37.1% of the patients, for intolerance or clinical criteria. A DAS28 remission (DAS28 <2.6) was observed only in 58.5% of the cases, while 52.9% of the patients still presenting an active form of the disease were on suboptimal doses of MTX. Conclusion: The weekly dose of MTX prescribed for the treatment of RA is often suboptimal, even in conditions of inadequate control of the disease activity. The recommendations for the use of MTX in RA patients should take into account the efficacy and tolerability data derived from its use in real clinical practice. © Clinical and Experimental Rheumatology 2015. Source
Pustorino G.,U.O.C. di Neuropsichiatria Infantile |
Spano M.,Aou Policlinico Universitario rtino |
Cigala V.,Aou Policlinico Universitario rtino |
Lamberti M.,Aou Policlinico Universitario rtino |
And 10 more authors.
Bollettino - Lega Italiana contro l'Epilessia | Year: 2010
Rufinamide is a new anti-epileptic drug used as adjunctive treatment of Lennox-Gastaut syndrome. The aim of the study was to give preliminary data about effectiveness and tolerability of rufinamide in a group of patients affected with Lennox-Gastaut syndrome and presenting with refractory seizures. Source